Retatrutide 5mg (Retatrutide 5mL vial + 3mL bac water)

What is Retatrutide
Retatrutide (LY-3437943) is an investigational, synthetic peptide developed by Eli Lilly. It is designed as a triple agonist of three key metabolic receptors: GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide), and glucagon receptors.

Mechanism of Action & Key Features

• By activating GLP-1, Retatrutide helps suppress appetite, slow gastric emptying, and improve insulin secretion.
• Activation of GIP further enhances insulin sensitivity and contributes to blood sugar control.
• The glucagon receptor component helps increase energy expenditure and fat oxidation, adding a potential fat-burning effect beyond what GLP-1/GIP alone provide.
• Structurally, it is a 39-amino acid peptide modified with a fatty diacid moiety, which extends its half-life and allows for once-weekly dosing.

Clinical Results & Potential Benefits

• In Phase 2 trials, participants with overweight or obesity achieved mean weight reductions of around 17.5% at 24 weeks.
• At higher doses and longer durations (48 weeks), weight reductions reached approximately 24.2%.
• Additional observed benefits include improved glycemic control, reduced insulin resistance, healthier lipid profiles, and possible reductions in liver fat (which may support liver health).

Administration & Status

• Retatrutide is administered via subcutaneous injection, once weekly.
• It is currently in late-stage clinical development for the treatment of obesity and type 2 diabetes.

Safety & Considerations

• The most common side effects reported are gastrointestinal issues such as nausea, vomiting, and diarrhea, particularly at higher doses.
• Long-term safety in diverse populations is still under investigation, and regulatory approval is pending.